-coated stents, in such patients are limited. In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. After PCI, patients were treated with 1 month of dual antiplatelet therapy, followed by single antiplatelet therapy. The primary outcome was a safety composite of death from
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. Patients at high risk for bleeding who undergo percutaneous coronary intervention (PCI) often receive bare-metal stents followed by 1 month of dual antiplatelet therapy. We studied a polymer-free and carrier-free drug-coated stent that transfers umirolimus (also known as biolimus A9), a highly lipophilic sirolimus <0.001). Among patients at high risk for bleeding who underwent PCI, a polymer-free umirolimus-coated stent was superior to a bare-metal stent with respect to the primary safety and efficacy end points when used with a 1-month course of dual antiplatelet therapy. (Funded by Biosensors Europe; LEADERS FREE ClinicalTrials.gov number, NCT01623180.).
Arteriosclerosis Anti-Infective Agents Arterial Occlusive Diseases Antibiotics, Antineoplastic Vascular Diseases Antineoplastic Agents Sirolimus Antifungal Agents Umirolimus To Top * For Patients and Families * For Researchers * For Study Record Managers * Home * RSS Feeds
Antifungal Agents Umirolimus To Top * For Patients and Families * For Researchers * For Study Record Managers * Home * RSS Feeds * Site Map * Terms and Conditions * Disclaimer * Customer Support * Copyright * Privacy * Accessibility * Viewers and Players * Freedom of Information Act * USA.gov * * HHS Vulnerability Disclosure * U.S
Arteriosclerosis Immunosuppressive Agents Arterial Occlusive Diseases Immunologic Factors Vascular Diseases Physiological Effects of Drugs Sirolimus Anti-Inflammatory Agents Umirolimus To Top * For Patients and Families * For Researchers * For Study Record Managers * Home * RSS Feeds